Milestone Pharmaceuticals’ (MIST) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Milestone Pharmaceuticals (NASDAQ:MIST) in a report published on Monday morning, Benzinga reports. The brokerage currently has a $25.00 target price on the stock.

Separately, Rodman & Renshaw began coverage on shares of Milestone Pharmaceuticals in a research note on Thursday, August 22nd. They issued a buy rating and a $9.00 target price on the stock.

Milestone Pharmaceuticals Trading Up 2.1 %

Shares of Milestone Pharmaceuticals stock opened at $1.48 on Monday. Milestone Pharmaceuticals has a 12-month low of $1.12 and a 12-month high of $3.52. The company has a market cap of $78.82 million, a price-to-earnings ratio of -1.18 and a beta of 1.72. The company has a current ratio of 19.13, a quick ratio of 19.13 and a debt-to-equity ratio of 1.61. The company’s 50-day moving average price is $1.46 and its 200-day moving average price is $1.53.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. On average, equities analysts expect that Milestone Pharmaceuticals will post -0.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets raised its stake in Milestone Pharmaceuticals by 177.0% in the first quarter. BNP Paribas Financial Markets now owns 16,900 shares of the company’s stock valued at $30,000 after purchasing an additional 10,800 shares in the last quarter. Valeo Financial Advisors LLC raised its stake in shares of Milestone Pharmaceuticals by 100.0% during the third quarter. Valeo Financial Advisors LLC now owns 20,000 shares of the company’s stock worth $30,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Lion Point Capital LP raised its stake in shares of Milestone Pharmaceuticals by 1.7% during the second quarter. Lion Point Capital LP now owns 2,340,207 shares of the company’s stock worth $3,089,000 after acquiring an additional 40,000 shares in the last quarter. 86.18% of the stock is owned by hedge funds and other institutional investors.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.